Appropriate pharmacotherapy at the end of life: Prescribing safely and only what is needed as part of whole‑person care by Krajnik, M et al.
654 POLISH ARCHIVES OF INTERNAL MEDICINE 2019; 129 (10)  
developed.3,8 Deprescription is defined as a sys‑
tematic process of identifying and discontinuing 
drugs in instances in which existing or potential 
harms outweigh existing or potential benefits 
within the context of an individual patients’ goal, 
current level of functioning, life expectancy, val‑
ues, and preferences.9 Appropriate deprescibing is 
one of the most important aspects of appropriate 
pharmacological management at the end of life.
In this issue of Polish Archives of Internal Medi-
cine (Pol Arch Intern Med), Grądalski10 reports his 
findings from a cross ‑sectional study assessing 
polypharmacy, overprescribing, and the incidence 
of potential pharmacological errors in patients 
at the time of referral to single Polish center of 
palliative care. All patients consecutively admit‑
ted to the palliative outpatient clinic and the free‑
‑standing 42 ‑bed hospice that predominantly pro‑
vided the care for the people close to dying be‑
tween August 1, 2016 and December 31, 2017 were 
enrolled. During the first appointment, the con‑
sultant in palliative medicine evaluated the cur‑
rent medications in the relation to age, progno‑
sis, length of care, and functional capacity, and 
documented all inconsistencies between the pa‑
tients’ clinical condition, the goals of care, symp‑
toms profile, and the medications taken. Medica‑
tions were defined as unnecessary or inappropri‑
ate if the time needed to obtain a clinically mean‑
ingful benefit was longer than the remaining sur‑
vival time, or the therapeutic target did not align 
with the preferences expressed by the patient re‑
garding the goals of care, or the harm caused by 
the treatment outweighed the expected bene‑
fit, especially if the risks arose before the ben‑
efit. Medications were reviewed also based on 
the commonly known DDIs checklists. During 
the first appointment, the adjustment of the ther‑
apy, including deprescription, was initiated and 
Most patients with chronic progressive diseases 
are treated with several drugs to modify their life‑
‑limiting illness(es), if still possible, and to relieve 
any symptoms caused by it (them).1 According to 
a European survey, patients with advanced can‑
cer who are taking opioids for moderate or severe 
pain are given 7.8 medications on average, and 
approximately 45% of patients receive unneces‑
sary or potentially unnecessary drugs.2 Polyphar‑
macy defined either by the use of 5 or more med‑
ications (including over ‑the ‑counter medicines) 
or by the inappropriateness of the prescription3 
raises risks of serious adverse effects and drug–
drug interactions (DDIs).4,5
A recent systematic review of studies reporting 
clinically significant DDIs involving medications 
used for symptom control, other than opioids 
given for pain management, in adults with ad‑
vanced cancer pointed to alterations in CYP450‑
‑dependent metabolism and overstimulation of 
serotonin receptors in the central nervous sys‑
tem as the main mechanisms.4 Clinical manifes‑
tations of identified DDIs included, among oth‑
ers, sedation, respiratory depression, serotonin 
syndrome, neuroleptic malignant syndrome, de‑
lirium, seizures, ataxia, liver and kidney failure, 
bleeding, cardiac arrhythmias, rhabdomyolysis. 
Similarly, systematic reviews reporting clinically 
significant DDIs involving opioid analgesics used 
for pain management also highlighted the need 
to avoid polypharmacy (if possible) because of 
the higher risk of serious adverse effects.5
There is evidence of the use of many unneces‑
sary medications in palliative care even among 
patients being in the final weeks of life,6,7 many 
of which can lead to harms in this frailest of pa‑
tient populations. Therefore, for those who will 
not benefit from some medications prescribed 
for them, the concept of deprescription has been 
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that may not be necessarily applicable in patients 
with a short life expectancy, unrealistic expecta‑
tion of patients and families (and clinicians), or 
the presence of side effects of the medication rec‑
ognized as problems requiring more medications. 
Some medications that do not offer any substan‑
tial benefit (like nitrates) or are no longer clini‑
cally indicated (such as diuretics / oral hypogly‑
cemic agents in people with massive weight loss 
and poor oral intake) remain on medication lists 
and will only cause harm late in life.
Prophylactic medications are considered for 
discontinuation. For example, stopping aspirin in 
the primary prevention rarely causes any clinical 
controversy. However, it does not mean that we 
always should stop all prophylactic medicines in 
every patient at his or her end of life.15 For exam‑
ple, anticoagulants can be used either as primary 
(in immobilised people at risk of lung emboly or 
preventing stroke in people with atrial fibrillation 
at risk of ischemic stroke) or secondary (in peo‑
ple at risk of recurrence of above mentioned com‑
plications) prevention. Continuing both kinds of 
prophylaxis with anticoagulants, even in people 
approaching death, can help prevent a new clinical 
complication that could abruptly decrease quality 
of life (like severe breathlessness in nonfatal lung 
emboli or hemiplegia in nonfatal stroke). What 
is more, the strategy of deprescribing should not 
be to stop all disease ‑modifying medications for 
comorbid conditions as they can contribute sub‑
stantially to maintaining quality of life. For ex‑
ample, angiotensin converting–enzyme inhibi‑
tors in heart failure can help prevent breathless‑
ness by limiting pulmonary congestion in lungs. 
Likwise, bronchodilatators can help minimize ex‑
acerbations in people with chronic obstructive 
lung disease.16,17
One of the most important principles of med‑
icine is not to cause harm. Palliative care should 
offer med ical care to a person in full recognition 
of her or his in dividual needs, aims, and values. 
Thus, removing unnecessary medications is eth‑
ically permissible and medically indicated as it 
can improve quality of life, and reduce avoidable 
morbidity.18,19
Lastly, a more general reflection. Dame Cicely 
Saunders, one of the greatest founders of mod‑
ern palliative care, developed her theory of total 
pain based on patients’ narratives on facing the 
end of life. Her view was that a failure to recog‑
nize the contribution of spiritual, psychological, 
and social domain to the well ‑being of the pa‑
tients may result in overwhelming suffering. We 
should remember that this kind of suffering ex‑
perienced by a person as a whole could not be re‑
lieved solely through medications.20
To conclude, there is a growing number of stud‑
ies demonstrating that polypharmacy is a fre‑
quent problem among patients even at the end 
of their life. Polypharmacy often does not assure 
better quality of life. On the contrary, it can lead 
to other symptoms / adverse events and increase 
the costs of treatment. Grądalski10 showed that 
the numbers of drugs / tablets used prior to ad‑
mission compared with those prescribed during 
the first palliative care consultation were count‑
ed. The median number of drugs used at refer‑
ral to palliative care was 7.0 (and 9.0 tablets) per 
day and polypharmacy (defined as ≥5 medica‑
tions) was found in 78.6% of patients. In about 
70% of patients, at least one inappropriately pre‑
scribed medication was found, most frequently 
due to unnecessary treatment in the setting of 
limited prognosis. Omission of key medications 
was also noted such as no coprescription of a lax‑
ative when opioids were prescribed (24%). Inter‑
estingly, the patients with the shortest progno‑
sis took more medications and tablets per day on 
referral (median number 8.0 and 10.0, respec‑
tively) while bed ‑bound patients, with the short‑
est life expectancy, or discharged from hospital 
more often had one or more potentially inappro‑
priate medication. Evaluation of the deprescrip‑
tion initiated during first appointment revealed 
that number of medications / tablets was dimin‑
ished on palliative care consultation by a medi‑
an of 1.0 / 2.0, while the subgroups with higher 
numbers of medication errors had a greater re‑
duction in the number of medications.
All these observations from a single Polish 
center of palliative care are in accordance with 
the studies showing the high burden of unnec‑
essary medicines at the end of life, even dur‑
ing the dying phase. A framework for consider‑
ing the changing balance for net effects of med‑
ications (benefits and harms) as a person’s life‑
‑limiting illness progresses was proposed 15 years 
ago.11 Based on that, every prescriber is asked to 
be clear about why a medication was commenced, 
what is the realistically expected benefit, the time 
frames to that benefit, and the time frames to any 
likely harms were it to be ceased. This framework 
seeks to apply the principles of primary, second‑
ary, and tertiary prevention to prescribers’ think‑
ing about the continued prescription of long ‑term 
medications. Many physicians seeing a patient 
for the first time will have difficulty establish‑
ing the therapeutic intent of many of the medi‑
cations for comorbid disease. Systematically un‑
derstanding the net effects of every medication 
prescribed, whether it is for the long ‑term man‑
agement of comorbid disease or for symptom con‑
trol, is a necessity for every person writing a pre‑
scription, dispensing the prescription, or admin‑
istering the medications.12 When measured pro‑
spectively, the immediate and short ‑term harms 
of symptom control medications have been sys‑
tematically underestimated in palliative care.13,14 
Pharmacists, nurses, and doctors all have the re‑
sponsibility to reduce the burden of iatrogenic 
harm in people with life ‑limiting illnesses.
Why is polypharmacy such a frequent phenom‑
enon among palliative care patients? There are 
many potential reasons, such as multiple comor‑
bidities usually treated by different specialists, ac‑
cording to guidelines usually recommending pleio‑
tropic treatment for every progressive disease, 
656 POLISH ARCHIVES OF INTERNAL MEDICINE 2019; 129 (10)
14 Currow DC, Vella ‑Brincat J, Fazekas B, et al. Pharmacovigilance in hos‑
pice/palliative care: rapid report of net clinical effect of metoclopramide. 
J Palliat Med. 2012; 15: 1071‑1075. 
15 Pasierski T. Modification of cardiovascular pharmacotherapy in palli‑
ative care patients with cancer: a narrative review. Pol Arch Intern Med. 
2017; 127: 687‑693. 
16 Cruz ‑Jentoft AJ, Boland B, Rexach L. Drug therapy optimization at the 
end of life. Drugs Aging. 2012; 29: 511‑521. 
17 Sobanski PZ, Alt‑Epping B, Currow DC, et al. Palliative care for peo‑
ple living with heart failure: European Association for Palliative Care Task 
Force expert position statement. Cardiovasc Res. 2019 Aug 6. [Epub ahead 
of print]. 
18 Garfinkel D, Zur ‑Gil S, Ben ‑Israel J. The war against polypharmacy: 
a new cost ‑effective geriatric ‑palliative approach for improving drug therapy 
in disabled elderly people. Isr Med Assoc J. 2007; 9: 430‑434.
19 Martínez ‑Sélles M, Villanueva PD, Smeding R, et al. Reflections on eth‑
ical issues in palliative care for patients with heart failure. European Journal 
of Palliative Care. 2017; 24: 18‑22.
20 Krajnik M. Whole person care: a hope for modern medicine? Pol Arch 
Intern Med. 2017; 127: 712‑714. 
polypharmacy and increased risk of drug inappro‑
priateness affect particularly older people with 
a poor prognosis and poor condition, and those 
referred to a hospice by hospitals. There is an ur‑
gent need to introduce education within nonspe‑
cialist palliative care on appropriate pharmaco‑
therapy for patients approaching death. Pharma‑
cists, nurses, and doctors all share the responsi‑
bility to reduce the burden of iatrogenic harms 
in people with life ‑limiting illnesses. It is also 
high time to introduce into healthcare system 
and clinical practice attitudes which allow clini‑
cians to recognize the key role of biopsychosocial 
and spiritual model of care especially for people 
facing end of their life.
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